Livforsakringsbolaget Skandia Omsesidigt Purchases 2,900 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Livforsakringsbolaget Skandia Omsesidigt boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 34.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,432 shares of the biopharmaceutical company's stock after purchasing an additional 2,900 shares during the period. Livforsakringsbolaget Skandia Omsesidigt's holdings in Regeneron Pharmaceuticals were worth $12,018,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Vanguard Group Inc. raised its position in Regeneron Pharmaceuticals by 1.0% in the first quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company's stock worth $8,595,268,000 after acquiring an additional 91,956 shares during the period. Capital International Investors raised its holdings in shares of Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company's stock worth $3,011,640,000 after purchasing an additional 213,038 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Regeneron Pharmaceuticals by 25.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company's stock valued at $868,757,000 after purchasing an additional 184,561 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Regeneron Pharmaceuticals by 12.4% during the second quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company's stock valued at $567,864,000 after purchasing an additional 59,769 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in Regeneron Pharmaceuticals by 23.8% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company's stock worth $525,804,000 after buying an additional 96,266 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company's stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company's stock, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, VP Jason Pitofsky sold 487 shares of the company's stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares of the company's stock, valued at approximately $4,498,280. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of the company's stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company's stock, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.48% of the company's stock.

Regeneron Pharmaceuticals Price Performance

REGN stock traded up $16.65 during midday trading on Friday, reaching $1,015.67. The company had a trading volume of 474,128 shares, compared to its average volume of 493,701. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20. The company has a market capitalization of $111.91 billion, a P/E ratio of 30.01, a P/E/G ratio of 3.45 and a beta of 0.12. The firm has a 50-day moving average price of $1,118.02 and a 200-day moving average price of $1,038.90.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts' consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business had revenue of $3.55 billion during the quarter, compared to analysts' expectations of $3.38 billion. During the same quarter in the previous year, the company earned $8.79 EPS. The business's quarterly revenue was up 12.3% compared to the same quarter last year. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on REGN shares. Guggenheim upped their price target on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a "buy" rating in a research report on Friday, August 2nd. Leerink Partners reiterated a "market perform" rating and set a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Canaccord Genuity Group reissued a "buy" rating and issued a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. Truist Financial reaffirmed a "buy" rating and issued a $1,200.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Finally, Royal Bank of Canada boosted their target price on shares of Regeneron Pharmaceuticals from $1,252.00 to $1,260.00 and gave the company an "outperform" rating in a report on Friday, October 4th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $1,119.00.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.